



## **DEL MAR PHARMACEUTICALS SELECTED TO PRESENT AT 10<sup>TH</sup> ANNUAL BIO INVESTOR FORUM**

VANCOUVER, BRITISH COLUMBIA--(August 16, 2011) Del Mar Pharmaceuticals is pleased to announce that the company has been selected to give a corporate presentation at the 10<sup>th</sup> Annual BIO Investor Forum, which is being held at the Palace Hotel in San Francisco, California on October 25-26, 2011.

Del Mar Pharmaceuticals was selected to present at the conference by a Selection Committee, comprised of leading institutional investors and industry analysts.

The BIO Investor Forum is a national investor conference featuring leading private and emerging public biotech companies. The meeting is designed to appeal to healthcare venture and private equity investors as well as the buy-side and sell-side investment community. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and mature biotechnology companies.

"We are pleased to accept this invitation as recognition of our success in advancing VAL-083 toward human clinical trials in refractory glioblastoma multiforme, the most common and aggressive form of brain cancer. The BIO Investor Form will provide our company with positive exposure to well-established members of the life sciences investment community and an opportunity to network with potential commercialization partners, stated Mr. Jeffrey Bacha, President & CEO of Del Mar Pharmaceuticals.

Further information about the 10<sup>th</sup> Annual BIO Investor Forum can be found on the conference website at [www.bio.org/investorforum](http://www.bio.org/investorforum).

### **About DelMar Pharma**

DelMar Pharma was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. Our lead asset, VAL-083, benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved as a cancer chemotherapeutic overseas. Efficacy has been demonstrated in a range of tumor types, including glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

For further information, please visit [www.delmarpharma.com](http://www.delmarpharma.com)  
or contact Jeffrey A. Bacha, President & CEO (604) 629-5989